ArticleFrontiers in pharmacology2026
3-hydroxyanthranilic acid suppresses colorectal cancer growth and enhances 5-fluorouracil sensitivity via the YY1-p53 and YY1-DKK4 axes.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The tryptophan metabolite 3-hydroxyanthranilic acid (3-HAA) has been reported to exert tumor-growth-inhibitory activity; however, its functional role and underlying mechanisms in colorectal cancer (CRC) remain largely unexplored. Methods: We measured 3-HAA levels in CRC tissues and evaluated its effects on CRC cell proliferation through exogenous administration. Mechanistic investigations were performed to identify its direct protein targets and downstream signaling pathways. The therapeutic potential of 3-HAA, alone and in combination with 5-fluorouracil (5-FU), was assessed both Results: 3-HAA exhibited depleted levels in CRC tissues, and its exogenous administration effectively suppressed the proliferation of multiple CRC cell lines. Through its binding to the Yin Yang 1 (YY1) transcription factor, it disrupted the YY1-p53 interaction, preserved p53 stability, and induced cell cycle arrest. Notably, Discussion: Our findings demonstrate that 3-HAA functions as a tumor suppressor in CRC by targeting the YY1-p53 axis and enhancing chemosensitivity to 5-FU. These results highlight the potential of 3-HAA as a promising therapeutic agent for CRC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.